| Date | Phase | Anouncement | Biotech | Pharma | Product | Disease | Country | Other |
|---|---|---|---|---|---|---|---|---|
| 2009-12-07 | I | Launch | Merrion Pharmaceuticals (USA) | Novo Nordisk (Denmark) | oral insulin analogue (NN1952) | type 1 and type 2 diabetes | Germany | See details |
| 2009-12-07 | III | Result | Gentium (Italy) | Defibrotide | hepatic veno-occlusive disease in recipients of stem cell transplants. | See details | ||
| 2009-12-06 | III | Result | Bayer HealthCare (Germany) | Rivaroxaban | venous thromboembolism | See details | ||
| 2009-12-04 | I | Result | Endotis Pharma (France) | EP42675 | extracorporeal circulation in cardiac surgery, percutaneous coronary intervention in acute coronary syndromes | See details | ||
| 2009-12-04 | II | Result | BiogenIdec (USA) | Roche (Switerland) | ocrelizumab (humanised monoclonal antibody that selectively binds to CD20 antigen) | relapsing-remitting multiple sclerosis (RRMS) | See details | |
| 2009-12-03 | IIb | Launch | Oxagen (UK) | OC000459 (oral CRTH2 (DP2) antagonist) The G-protein coupled receptor, CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells also known as DP2) mediates allergic responses by interaction with the mast cell product prostaglandin D2. | asthma | See details | ||
| 2009-12-03 | III | Result | Roche (Switzerland) | taspoglutide (glucagon-like-peptide-1 (GLP-1) analogue) Roche exercised its licensing option for taspoglutide from Ipsen in 2006 and acquired exclusive worldwide rights to develop and market taspoglutide, except in Japan where these rights are shared with Teijin and in France where Ipsen retained co-marketing rights | diabetes | See details | ||
| 2009-12-01 | II | Result | Agennix (Germany) | talactoferrin | severe sepsis | USA | See details | |
| 2009-11-30 | III | Launch | Bayer HealthCare (Germany) | florbetaben PET Tracer | Alzheimer's disease | worldvide study on four different continents | See details | |
| 2009-11-27 | II | Launch | Lundbeck (Denmark) | Lu AE58054 (5-HT6-receptor antagonist) | moderate Alzheimer's disease | See details | ||
| 2009-11-27 | II | Result | Biovitrum (Sweden) | Kiobrina® (recombinant human bile-salt-stimulated lipase - rhBSSL) | enzyme replacement therapy to improve growth and development in preterm infants receiving pasteurized breast milk and/or formula | See details | ||
| 2009-11-25 | I | Launch | Glycotope (Germany) | GT-MAB 2.5-GEX® (monoclonal antibody directed against a novel tumor-specific combined carbohydrate-protein epitope present in a large number of patients of various cancers) Its fully human glycosylation was achieved by Glycotope´s proprietary technology platform GlycoExpress®, a screening and high yield production system of glycoengineered human cell-lines that allows significant enhancement of therapeutic potency by optimizing a protein’s glycosylation in various aspects. | cancers | Germany, Italy | See details | |
| 2009-11-25 | II | Launch | Ipsen (France) | BN83495 (first-in-class steroid sulfatase (STS) inhibitor) This compound is currently in further clinical development for postmenopausal metastatic breast cancer as well as in PI/II clinical development for castrate resistant prostate cancer. Ipsen plans to expand the clinical program to include ovarian cancers in the near future. | advanced endometrial cancer | See details | ||
| 2009-11-25 | IIa | Launch | vasopharm (Germany) | VAS203 (NO-synthase inhibitor) | traumatic brain injury | Europe | See details | |
| 2009-11-23 | III | Result | Biotec Pharmacon (Norway) | soluble beta-glucan (SBG) | diabetic foot ulcers | See details |
